Argenx Halts Sjögren’s Drug Trial, Shares Plunge Amid Volatility
Argenx announced the halt of its Phase 2 clinical trial for a Sjögren’s syndrome drug, citing futility. This news, confirmed by the company, initially caused a significant plunge in Argenx's stock price, with one report noting a 16% drop. However, subsequent reporting from Investing.com questioned reasons for a stock rally, indicating a complex and potentially conflicting market reaction.
3 articles from 2 outlets covered this story. Their coverage differs on 2 points. The underlying claim is sourced from a press release.
What do all outlets agree on?
2 outlets covered “Argenx Halts Sjögren’s Drug Trial, Shares Plunge Amid Volatility”. All of them report the following:
- Argenx halted its Sjögren’s drug trial
- The trial was for an autoimmune disease
- Argenx shares reacted significantly to the news
Did outlets disagree about this?
Yes. Coverage of “Argenx Halts Sjögren’s Drug Trial, Shares Plunge Amid Volatility” differs on 2 points. Each account below is how a different outlet described the same event:
Argenx shares plunged
Argenx stock is rallying
Which outlets covered this?
All 3 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.